Psoriasis can affect different body parts, including the scalp, elbows ... This includes over-the-counter and prescription-strength creams. For many people with mild psoriasis, dermatologists ...

according to the analysis of patients with plaque psoriasis. “We typically don’t think about putting cream on the scalp,” she added, but additional research looking at this PAD-formulated ...

ZORYVE foam is under review for the treatment of scalp and body psoriasis by the FDA with a PDUFA target action date of May 22, 2025. ZORYVE cream, 0.3%, is indicated for topical treatment of ...

Data demonstrated favorable safety and local tolerability of ZORYVE ® (roflumilast) cream 0.15% in adults ... and local tolerability data in scalp and body psoriasis In the United States, AD ...

A new treatment could bring a smile to the faces of thousands who suffer from the skin disease psoriasis. Improved drugs are already bringing better control of the condition to many patients.

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Interestingly, while overall scalp symptoms were comparable between subgroups, the total Scalpdex score was numerically worse in the BSA 3% to 10% group (57.5 [21.1] vs 49.7 [22.2]), suggesting ...

It also won Best of Show and Best Use of Insight for its patient and public awareness work for Leo Pharma – the ‘Give Nothing to Psoriasis’ campaign. This focuses on heart-rending stories ...

This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through ...

statements regarding the potential of ZORYVE foam and regulatory timing for FDA approval based on the PDUFA for the treatment of scalp and body psoriasis, the potential for clinical results for ZORYVE ...